THESEUS PHARMACEUTICALS, INC.

(THRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2022 05/19/2022 05/20/2022 05/23/2022 05/24/2022 Date
7.35(c) 6.99(c) 7.16(c) 7.26(c) 6.95(c) Last
24 713 106 502 91 542 73 949 68 909 Volume
-8.35% -4.90% +2.43% +1.40% -4.27% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -49,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,52x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -71,2 M - -
Net Debt 2023 - - -
P/E ratio 2023 -4,01x
Yield 2023 -
Capitalization 264 M 264 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 26
Free-Float 96,4%
More Financials
Company
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on treating cancer patients through the discovery, development and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in oncogenes, which are mutated genes that cause cancer. The Company is focused on developing tyrosine kinase inhibitors (TKI), which is rooted in the... 
Sector
Biotechnology & Medical Research
Calendar
06/09 | 04:30pmPresentation
More about the company
Ratings of Theseus Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about THESEUS PHARMACEUTICALS, INC.
05/19Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
PR
05/18THESEUS PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial State..
AQ
05/18Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
PR
05/18Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
CI
05/12THESEUS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condit..
AQ
05/12Theseus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended Marc..
CI
04/08Theseus Pharmaceuticals, Inc. Announces Preclinical Data Characterizing Next-Generation..
CI
04/05Theseus Pharmaceuticals to Participate Virtually in Needham Healthcare Conference
PR
04/05Certain Options of Theseus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement End..
CI
04/05Certain Common Stock of Theseus Pharmaceuticals, Inc. are subject to a Lock-Up Agreemen..
CI
04/04Vipergen ApS Establishes DNA Encoded Library-Based Drug Discovery Partnership with Thes..
CI
03/20THESEUS PHARMACEUTICALS, INC.(NASDAQ : THRX) added to S&P Global BMI Index
CI
03/10Theseus Pharmaceuticals Q4 Loss Narrows; Shares Down Midday
MT
03/10THESEUS PHARMACEUTICALS : Announces Business Highlights and Reports Fourth Quarter and Ful..
PU
03/10THESEUS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condit..
AQ
More news
News in other languages on THESEUS PHARMACEUTICALS, INC.
05/18Theseus Pharmaceuticals nomme Don Hayden au conseil d'administration
05/12Theseus Pharmaceuticals, Inc. publie ses résultats pour le premier trimestre clos le 31..
04/08Theseus Pharmaceuticals, Inc. annonce des données précliniques caractérisant la prochai..
04/04Vipergen ApS établit un partenariat de découverte de médicaments basés sur des biblioth..
03/10La perte du quatrième trimestre de Theseus Pharmaceuticals diminue ; les actions baisse..
More news
Analyst Recommendations on THESEUS PHARMACEUTICALS, INC.
More recommendations
Chart THESEUS PHARMACEUTICALS, INC.
Duration : Period :
Theseus Pharmaceuticals, Inc. Technical Analysis Chart | THRX | US88369M1018 | MarketScreener
Technical analysis trends THESEUS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 6,95 $
Average target price 21,50 $
Spread / Average Target 209%
EPS Revisions
Managers and Directors
Timothy P. Clackson President, Chief Executive Officer & Director
Bradford D. Dahms Chief Financial Officer
Iain David Dukes Chairman
William C. Shakespeare Director & President-Research & Development
Victor M. Rivera Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
THESEUS PHARMACEUTICALS, INC.-45.19%264
GILEAD SCIENCES, INC.-11.38%80 715
REGENERON PHARMACEUTICALS, INC.8.63%73 916
VERTEX PHARMACEUTICALS22.26%68 665
WUXI APPTEC CO., LTD.-22.20%40 017
BIONTECH SE-40.07%37 546